Diuretic effects of cannabinoids

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 8-14

  Paronis, Carol A ^a,b   Thakur, Ganesh A ^a   Bajaj, Shama ^a   Nikas, Spyros P ^a   Vemuri, V Kiran ^a   Makriyannis, Alexandros ^a   Bergman, Jack ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; [9BETA (HYDROXYMETHYL) 3 (1 ADAMANTYL)HEXAHYDROCANNABINOL]; [9BETA HYDROXY 3 (1 HEXYL CYCLOBUT 1 YL)HEXAHYDROCANNABINOL]; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CAPSAZEPINE; DRONABINOL; FUROSEMIDE; METHANANDAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; PENTOBARBITAL; RIMONABANT; UNCLASSIFIED DRUG; WIN 55 212;

ANIMAL EXPERIMENT; ARTICLE; COLON TEMPERATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; INDUCED HYPOTHERMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE; URINE VOLUME;

ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; BODY TEMPERATURE; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; CONFIDENCE INTERVALS; DIURESIS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; WATER;

EID: 84871706165     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199331     Document Type: Article

References (44)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, and Makriyannis A (1994) (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893. (Pubitemid 24219781)
2. Allentuck S and Bowman KM (1942) The psychiatric aspects of marihuana intoxication. Am J Psychiatry 99:248-251.
3. Ames F (1958) A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. J Ment Sci 104:972-999.
4. Apostolidis A (2012) Taming the cannabinoids: new potential in the pharmacologic control of lower urinary tract dysfunction. Eur Urol 61:107-109, discussion 109-111.
5. Avelino A and Cruz F (2006) TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol 373:287-299. (Pubitemid 43999780)
6. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, and Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097. (Pubitemid 27371630)
7. Bosier B, Sarre S, Smolders I, Michotte Y, Hermans E, and Lambert DM (2010) Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodynamic differences between cannabinoid agonists. Neuropharmacology 59 :503-510.
8. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, and Fowler CJ (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10:425-433. (Pubitemid 39117340)
9. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, and Prather PL (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 83:952-961.
10. Compton DR, Aceto MD, Lowe J, and Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594. (Pubitemid 27168965)
11. Compton DR, Gold LH, Ward SJ, Balster RL, and Martin BR (1992) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126. (Pubitemid 23157189)
12. Consroe P, Musty R, Rein J, Tillery W, and Pertwee RG (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38:44-48. (Pubitemid 27283078)
13. Davis TRA, Kensler CJ, and Dews PB (1973) Comparison of behavioral effects of nicotine, d-amphetamine, caffeine and dimethylheptyl tetrahydrocannabinol in squirrel monkeys. Psychopharmacology (Berl) 32:51-65.
14. De Vry J, Jentzsch KR, Kuhl E, and Eckel G (2004) Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15:1-12. (Pubitemid 38241508)
15. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613. (Pubitemid 19007296)
16. Di S, Boudaba C, Popescu IR, Weng FJ, Harris C, Marcheselli VL, Bazan NG, and Tasker JG (2005) Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. J Physiol 569:751-760. (Pubitemid 41830220)
17. Dinis P, Charrua A, Avelino A, Yaqoob M, Bevan S, Nagy I, and Cruz F (2004) Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 24:11253-11263. (Pubitemid 39658260)
18. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
19. Järbe TUC, Liu Q, and Makriyannis A (2006) Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology (Berl) 184:36-45. (Pubitemid 43005755)
20. Justinova Z, Solinas M, Tanda G, Redhi GH, and Goldberg SR (2005) The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci 25:5645-5650. (Pubitemid 40800656)
21. Li J and Wang DH (2006) Differential mechanisms mediating depressor and diuretic effects of anandamide. J Hypertens 24:2271-2276. (Pubitemid 44611037)
22. Makwana R, Molleman A, and Parsons ME (2010) Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol 160:615-626.
23. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, and Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478.
24. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211-1218.
25. McMahon LR and Koek W (2007) Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur J Pharmacol 569:70-76. (Pubitemid 47175872)
26. Meschler JP, Kraichely DM, Wilken GH, and Howlett AC (2000) Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5- (4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem Pharmacol 60:1315-1323.
27. Nikas SP, Alapafuja SO, Papanastasiou I, Paronis CA, Shukla VG, Papahatjis DP, Bowman AL, Halikhedkar A, Han X, and Makriyannis A (2010) Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl- cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem 53:6996-7010.
28. Parker CS and Wrigley F (1947) Effects of cannabis. Lancet 2 :223.
29. Powers WJ (2001) Renal Toxicology, in CRC Handbook of Toxicology, 2nd ed (Derelanko MJ and Hollinger M eds) Informa Healthcare. doi:10.1201/ 9781420042078.ch10
30. Rinaldi-Carmona M, Barth F, and Héaulme M, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244. (Pubitemid 24268029)
31. Schlosburg JE, Carlson BLA, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, and Lichtman AH (2009) Inhibitors of endocannabinoid-metabolizing enzmes reduce precipitated withdrawal responses in THC-dependent mice. AAPSPharm Sci 11:342-352.
32. Sim-Selley LJ, Brunk LK, and Selley DE (2001) Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135-143. (Pubitemid 32181880)
33. Sofia RD, Knobloch LC, Harakal JJ, and Erikson DJ (1977) Comparative diuretic activity of delta9-tetrahydrocannabinol, cannabidiol, cannabinol and hydrochlorothiazide in the rat. Arch Int Pharmacodyn Ther 225:77-87. (Pubitemid 8054205)
34. Soya A, Serino R, Fujihara H, Onaka T, Ozaki Y, Saito T, Nakamura J, and Ueta Y (2005) Cannabinoids modulate synaptic activity in the rat supraoptic nucleus. J Neuroendocrinol 17:609-615. (Pubitemid 41195415)
35. Stockings GT (1947) A new euphoriant for depressive mental states. BMJ 1:918-922.
36. Strittmatter F, Gandaglia G, Benigni F, Bettiga A, Rigatti P, Montorsi F, Gratzke C, Stief CG, Colciago G, and Hedlund P (2012) Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats. Eur Urol 61:98-106.
37. Thakur GA, Bajaj S, Paronis CA, Wood JA, Barak L, Peng Y, Parish D, and Makriyannis A (2012)Novel adamantyl cannabinoids as CB1 receptor probes. J Med Chem (under review).
38. Touw M (1981) The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs 13:23-34.
39. Tyagi V, Philips BJ, Su R, Smaldone MC, Erickson VL, Chancellor MB, Yoshimura N, and Tyagi P (2009) Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181:1932-1938.
40. Walczak J-S, Price TJ, and Cervero F (2009) Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity. Neuroscience 159:1154-1163.
41. Wiley JL, Jefferson RG, Grier MC, Mahadevan A, Razdan RK, and Martin BR (2001) Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation. J Pharmacol Exp Ther 296:1013-1022. (Pubitemid 32187377)
42. Wiley JL, Marusich JA, Martin BR, and Huffman JW (2012) 1-Pentyl-3- phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice, Drug Alc Depend. 123:148-153
43. Wiley JL, O'Connell MM, Tokarz ME, and Wright MJ, Jr (2007) Pharmacological effects of acute and repeated administration of Delta(9)-tetrahydrocannabinol in adolescent and adult rats. J Pharmacol Exp Ther 320:1097-1105. (Pubitemid 46294066)
44. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, and Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785. (Pubitemid 29234695)